Literature DB >> 32830809

Nasal chemosensory tests: biomarker between dementia with Lewy bodies and Parkinson disease dementia.

C Foguem1, M Lemdani2, C Huart3.   

Abstract

BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) are progressive and disabling neurodegenerative disorders, which are often misdiagnosed due to theirs overlapping clinical and paraclinical features. Nevertheless, their adequate management requires an accurate differential diagnosis. The main aim of this study was to investigate the usefulness of olfactory and trigeminal nasal testing for the differential diagnosis between DLB and PDD.
METHODS: Odor thresholds to three odorants differentially activating the olfactory and trigeminal systems were assessed in patients with DLB, PDD and healthy controls (n = 20 per group).
RESULTS: Odor thresholds were significantly different between the three groups of subjects. More precisely, we found that DLB patients had significantly lower detection threshold performances compared to PDD patients. Moreover, using a standard canonical discriminant analysis, we confirmed a plain differentiation between the three groups.
CONCLUSIONS: The current study highlights that DLB patients have very poor olfactory and trigeminal detection threshold performances, which are significantly lower, compared to PDD patients. These results suggest that olfactory testing, using odorants that stimulate both the olfactory and trigeminal systems, could constitute an interesting biomarker and contribute to the differential diagnosis of PDD and DLB patients. Further researches, notably on olfacto-trigeminal interactions, are warranted in these populations to support our findings.

Entities:  

Year:  2020        PMID: 32830809     DOI: 10.4193/Rhin20.072

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  4 in total

1.  Quantitative but not qualitative flavor recognition impairments in COVID-19 patients.

Authors:  Immacolata Cristina Nettore; Elena Cantone; Giuseppe Palatucci; Fabiana Franchini; Rufina Maturi; Mariagiovanna Nerilli; Elio Manzillo; Maria Foggia; Luigi Maione; Paola Ungaro; Annamaria Colao; Paolo Emidio Macchia
Journal:  Ir J Med Sci       Date:  2021-09-25       Impact factor: 2.089

2.  The temporal course of COVID-19 anosmia and relation to other clinical symptoms.

Authors:  Aytug Altundag; Ozlem Saatci; Deniz Esin Tekcan Sanli; Ozge Arici Duz; Ahmet Necati Sanli; Oktay Olmuscelik; Dastan Temirbekov; Sedat Giray Kandemirli; Aysegul Batioglu Karaaltin
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-11-25       Impact factor: 2.503

3.  Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell.

Authors:  Serge-Daniel Le Bon; Deborah Konopnicki; Nathalie Pisarski; Léa Prunier; Jérôme R Lechien; Mihaela Horoi
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-09       Impact factor: 2.503

Review 4.  Chemosensory dysfunction in primary Sjögren's syndrome: a topical review.

Authors:  C Foguem; R Seror; M Gosset
Journal:  Clin Rheumatol       Date:  2022-09-05       Impact factor: 3.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.